Statins Over 70?: New Study Clears Up the Confusion

Main ideas / concepts / lessons

• Clinical question addressed: Whether lowering LDL cholesterol with statins is beneficial in an elderly population (especially age > 70, including late 70s/80s).
• Why evidence was historically limited:
  • Older adults have less remaining time to benefit from long-term cholesterol exposure (i.e., time-to-event changes).
  • They often have more comorbidities, take multiple medications, and may have had previous adverse effects, complicating interpretation of risks vs. benefits.
  • The speaker notes a common counseling approach: after ~age 75, if someone has not had major cardiovascular events (e.g., MI, stroke) or procedures (e.g., stent, bypass), clinicians may consider forgoing cholesterol-lowering medications—though decisions should be individualized.
• New study highlighted: A randomized trial in Australia (published in the New England Journal of Medicine) testing a statin in people aged 70–80s.

Methodology / what the study did

• Study design

  • Randomized, placebo-controlled trial
  • Conducted in a general medical population (not university-based)
  • Approximately 10,000 participants
  • Randomized 1:1 to:
    • Tovastatin 40 mg daily (the speaker refers to it as “tovvis statin”; likely meaning atorvastatin or another similarly named statin)
    • Placebo
  • Follow-up: median of ~6 years

• Primary outcomes

  • Primary endpoint #1: MACE
    • MACE = major adverse cardiovascular and cerebrovascular events, including:
      • Heart attack
      • Stroke
      • Coronary revascularization (e.g., stent placement or bypass surgery)
  • Primary endpoint #2: composite later outcomes
    • Death from any cause
    • Onset of dementia
    • Persistent physical disability
  • These later outcomes were measured using prespecified scales and assessed independently.

• Additional safety concerns examined

  • Dementia risk
  • Diabetes onset
  • Musculoskeletal pain / disability

• Baseline characteristics (approximate)

  • Average age: ~75
  • Sex: ~52% female
  • BMI: mean ~27; about 26% with BMI >30 (obese range)
  • Baseline LDL: ~127 mg/dL (not extremely high)
  • Musculoskeletal pain at baseline: 46%

• LDL reduction results

  • Statin group: mean LDL reduction ~48 mg/dL
  • Placebo group: mean LDL reduction ~16 mg/dL
  • The speaker suggests the placebo reduction likely reflects placebo effect and trial-related diet/exercise improvements.

• Cross-over complication

  • Approximately 19–20% of participants assigned to placebo were actually taking a statin by year 5
  • This reduces the observable difference between groups and can make benefits/harms harder to detect.

• Efficacy results

  • MACE event rates:
    • 10.9 events per 1,000 patient-years (statin)
    • 15.5 events per 1,000 patient-years (placebo)
  • Second primary endpoint: no difference between groups for the composite outcome of death/dementia/disability.

• Safety / adverse event findings (as described)

  • The placebo group favored on some adverse outcomes:
    • Higher rate of hpatobiliary disorders in the statin group (details unclear in the provided summary)
    • Higher onset of diabetes in the statin group
  • Uncertainty in reporting details:
    • Liver enzyme/transaminase elevations likely underlie “hpatobiliary disorders,” but study details weren’t fully clear in the provided description.
    • Diabetes reporting details (e.g., glucose/A1C changes vs. formal diagnosis) were also not fully delineated.

Interpretation / implications for practice (speaker’s “two cents”)

• Benefit in the elderly is supported:

  • The trial fills a long-standing evidence gap about LDL lowering in older adults.
  • Earlier studies often emphasized younger populations; subanalyses suggested the elderly may receive about half the benefit.
  • The speaker contrasts this with the older Lancet PROSPER study (pravastatin 40 mg) in elderly participants:
    • ~2% absolute risk reduction
    • ~20% relative risk reduction
  • The new study is described as showing a more profound effect than the speaker expected, while remaining broadly consistent with overall statin evidence.

• How it affects “stopping statins” after ~75

  • A shift toward keeping the conversation open rather than assuming stopping is automatic.
  • Core principle: decisions should be a shared physician–patient discussion based on expected benefit, risk, and patient preferences.
  • Likely reasons some older adults discontinue include:
    • Polypharmacy
    • Desire to reduce medication burden

• Addresses misinformation about statins causing dementia

  • The study reportedly found no difference in dementia onset between statin and placebo.
  • No difference was found in significant musculoskeletal disability, countering claims of major disabling side effects.

• Response to anti-industry / kickback concerns

  • The speaker argues that kickback concerns are less compelling for statins because:
    • Statins are generic
    • personal experience: “never had a kickback”
    • no awareness of widespread kickbacks specifically for statins

• US insurance reality influencing treatment choices

  • The speaker suggests that, if unrestricted, they might prefer PCSK9 inhibitors due to potentially fewer adverse events.
  • However, insurance often requires failure of two statins plus Zetia (ezetimibe) before approval, and denials are common.
  • As a result, statins often remain first-line mainly due to coverage/authorization rules, not necessarily because they’re the best drug for every patient.

Speakers / sources featured

• Speaker: Phil Datillo, interventional cardiologist (interest in preventive cardiology)
• Named sources/publications:
  • New England Journal of Medicine (trial described)
  • The Lancet (PROSPER study mentioned)
• Trial-related treatments mentioned:
  • Tovastatin / “tovvis statin” 40 mg (speaker wording; context indicates statin used in the NEJM trial)
  • Pravastatin 40 mg (PROSPER study)
• Other medication classes referenced:
  • PCSK9 inhibitors
  • Zetia (ezetimibe)
  • Transaminases / liver enzymes (as likely mechanism behind “hpatobiliary disorders”)
• Common outcome acronym used:
  • MACE (major adverse cardiovascular and cerebrovascular events)